Key result
Novel purinedione derivatives inhibit platelet aggregation more effectively than aspirin in preclinical testing.
Why the study?
1-Isobutylpurine-2,6-diones have broad pharmacological activities, but detailed stereochemical analysis and antiplatelet activity of thietane-containing derivatives were not established.
Do novel thietane-containing 1-isobutylpurine-2,6-dione derivatives inhibit ADP-induced platelet aggregation more effectively than acetylsalicylic acid in vitro?
Do novel thietane-containing 1-isobutylpurine-2,6-dione derivatives inhibit ADP-induced platelet aggregation more effectively than acetylsalicylic acid in vitro?
Synthesized thietane-containing 1-isobutylpurine-2,6-dione derivatives, particularly compound 6b, demonstrated greater in vitro inhibition of ADP-induced platelet aggregation than acetylsalicylic acid, representing potential candidates for novel GPIIb/IIIa-targeted antiplatelet agents.
Warrants further preclinical testing of these derivatives; leaves open their viability as next-generation antiplatelet agents.
1-Isobutylpurine-2,6-diones possess a broad spectrum of pharmacological activities, highlighting their relevance in the search for new biologically active agents. In this study, we report the synthesis of a series of novel thietane-containing 1-isobutylpurine-2,6-dione derivatives. A crucial aspect of this work is the detailed stereochemical and conformational analysis of the thietanyl substituent. For the first time, the unambiguous assignment of axial and equatorial protons within the thietane ring was achieved using 2D NMR spectroscopy, exemplified by a comprehensive study of the starting substance. Furthermore, the newly synthesized compounds were evaluated for their antiplatelet activity, revealing inhibition of platelet aggregation exceeding that of acetylsalicylic acid. Based on structural analogy to an established antiplatelet agent, we hypothesize that the observed biological effect is mediated via the inhibition of the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor complex. These findings demonstrate that the incorporation of a thietane fragment into the 1-isobutylxanthine scaffold yields promising candidates for the development of novel GPIIb/IIIa-targeted antiplatelet therapeutics.
No takes yet. Share an insight, caveat, or question.
Халиуллин et al. (2026) studied In vitro platelet aggregation in healthy donors (n=21). 8-amino-substituted 1-isobutyl-3-methyl-3,7-dihydro-1H-purine-2,6-diones containing a thietane ring (compounds 6a-o) vs. Acetylsalicylic acid was evaluated on Maximum amplitude (MA) in ADP-induced platelet aggregation test (p=<0.05). Novel thietane-containing 1-isobutylpurine-2,6-dione derivatives (6b, 6c, 6f) inhibited ADP-induced platelet aggregation more strongly than acetylsalicylic acid (MA 13.7 vs 16.2-19.6, p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: